Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), announced today that shareholders approved all management proposals with a large majority at the company's ordinary virtual Annual General Meeting held on June 23, 2026. The approval rates ranged between 98.67% and 98.72%, reflecting strong shareholder support for the company's strategic direction.
Key resolutions included the formal approval of the actions of the Management Board and Supervisory Board for the 2024/2025 financial year, the appointment of auditors for the 2025/2026 financial year, and the approval of the remuneration report for the Management Board. Shareholders also elected Mr. Jack Yefei Ling as a new member of the Supervisory Board and approved an amendment to the Articles of Association to reduce the size of the Supervisory Board from seven to five members.
The meeting saw high shareholder engagement, with attendance (including postal votes) reaching 80.55% of the current capital stock. Detailed voting results are available on the company's website at https://heidelberg-pharma.com/en/agm.
Heidelberg Pharma is a pioneer in developing cancer therapies using Amanitin, a toxin derived from the green death cap mushroom. The company's proprietary ATAC technology leverages this novel mechanism of action to create Antibody Drug Conjugates. Its lead candidate, HDP-101 (INN: pamlectabart tismanitin), is a BCMA-targeting ATAC in clinical development for multiple myeloma and has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA. A second candidate, HDP-102, is in clinical development for Non-Hodgkin Lymphoma, while HDP-103 (metastatic castration-resistant prostate cancer) and HDP-104 (gastrointestinal tumors such as colorectal cancer) have completed preclinical development and are available for partnering.
The approval of the remuneration report and the election of Mr. Ling signal continued shareholder confidence in the company's governance and strategic direction. The reduction in the Supervisory Board size may streamline decision-making as the company advances its clinical pipeline. For further information about Heidelberg Pharma, visit www.heidelberg-pharma.com.
